Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

115.61 UNCHANGED
Official Closing Price Updated: 7:00 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 919,170
Open 115.86
Bid (Size) 113.08 (1)
Ask (Size) 115.83 (1)
Prev. Close 115.61
Today's Range 115.60 - 116.39
52wk Range 92.19 - 120.92
Shares Outstanding N/A
Dividend Yield 3.00%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Importance of Managing Bad Cholesterol: What You Should Know
(BPT) - Sponsored by Novartis Pharmaceuticals Corporation 
Via Brandpoint
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety

Performance

YTD
+14.47%
+14.47%
1 Month
-3.64%
-3.64%
3 Month
+8.59%
+8.59%
6 Month
+20.59%
+20.59%
1 Year
+12.98%
+12.98%

More News

Read More
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire
Balancing Dividends and Fundamentals: The Case of NYSE:NVS.
Via Chartmill
NYSE:NVS: good value for what you're paying.
Via Chartmill
Embassy of Italy in Singapore Presents ‘Superstar’ Architect Michele De Lucchi for Singapore Design Week 2024
Via AB Newswire
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Via FinancialNewsMedia
Uncovering Dividend Opportunities with NYSE:NVS.
Via Chartmill
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
From FN Media Group LLC
Via GlobeNewswire
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
Via Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Via Benzinga
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Via Benzinga
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
Via Benzinga
S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study
Via Benzinga
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
From Lindy Biosciences
Via Business Wire
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
Via Investor's Business Daily
Exposures Product Safety
Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal
Via Benzinga
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
Via The Motley Fool
Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS